Horizant is a medication prescribed for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of post-herpetic neuralgia (PHN) pain in adults [1]. It is also approved for the treatment of moderate-to-severe knee pain associated with osteoarthritis [2]. Horizant's active ingredients are gabapentin enacarbil and historically, extended-release tramadol [3][4]. The gabapentin enacarbil component is a prodrug of gabapentin [1].
How Does Horizant Work for Restless Legs Syndrome?
The exact mechanism by which gabapentin enacarbil alleviates RLS symptoms is not fully understood. However, it is believed to modulate the activity of neurotransmitters in the brain that are involved in motor control and sensory processing [1]. The extended-release formulation is designed to provide a consistent level of the medication in the body throughout the night, which is when RLS symptoms are often most severe [5].
What Are the Other Uses for Horizant?
Beyond restless legs syndrome, Horizant is used to manage pain associated with post-herpetic neuralgia, a chronic nerve pain condition that can occur after a shingles infection [1]. It is also indicated for reducing moderate-to-severe knee pain linked to osteoarthritis [2].
What Are the Potential Side Effects of Horizant?
Common side effects of Horizant can include dizziness, somnolence (sleepiness), fatigue, and nausea [1]. More serious side effects are possible and may include severe allergic reactions, suicidal thoughts or behavior, and mood changes [1]. Patients should consult their healthcare provider about any side effects they experience.
When Does Patent Protection for Horizant Expire?
Patent information for medications like Horizant can be complex and may involve multiple patents covering different aspects of the drug, such as its formulation, method of use, or manufacturing process. Information regarding specific patent expiration dates and any ongoing patent challenges can be found on resources like DrugPatentWatch.com [6]. Historically, patent exclusivities can vary significantly, impacting when generic versions might become available [7].
Are There Generic Alternatives to Horizant?
The availability of generic alternatives depends on the expiration of relevant patents and regulatory approvals. For medications with gabapentin enacarbil as an active ingredient, generic versions may become available following patent expiry. The availability of generic tramadol extended-release formulations also exists [7].
How Does Horizant Compare to Other RLS Treatments?
Other treatments for restless legs syndrome include dopamine agonists (like pramipexole and ropinirole), alpha-2 delta ligands (like gabapentin and pregabalin), and iron supplementation for those with iron deficiency [8]. Horizant, containing gabapentin enacarbil, falls into the alpha-2 delta ligand category but is formulated for extended release to manage RLS symptoms, particularly at night [1][5]. The choice of treatment depends on the individual's symptom severity, medical history, and potential side effects [8].
What is the Regulatory Status of Horizant?
Horizant is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses [1][2]. The FDA's approval signifies that the drug has met standards for safety and effectiveness for its approved indications.
What Clinical Data Supports Horizant's Efficacy?
Clinical trials have demonstrated the efficacy of Horizant in reducing the symptoms of restless legs syndrome, post-herpetic neuralgia, and osteoarthritis knee pain [1][2]. These studies typically involve placebo-controlled designs to assess the drug's benefits against no treatment [1][2].
What are Patient Concerns Regarding Horizant?
Patients often have concerns about potential side effects, particularly drowsiness and dizziness, which can impact daily activities and driving [1]. Concerns about long-term use, dependency, and the effectiveness of the medication over time are also common [8]. Discussing these concerns with a healthcare provider is crucial for informed decision-making.
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022302s022lbl.pdf
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209448lbl.pdf
3. https://www.drugpatentwatch.com/medications/horizant
4. https://www.drugpatentwatch.com/drugs/gabapentin-enacarbil
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367135/
6. https://www.drugpatentwatch.com/
7. https://www.drugpatentwatch.com/news/latest-drug-patent-news
8. https://www.mayoclinic.org/diseases-conditions/restless-legs-syndrome/diagnosis-treatment/drc-20377200